Pfizer (PFE)
Developer of prescription medicines and vaccines across oncology, internal medicine, immunology and infectious disease.
Something off on this page? Send us feedback.
Develops and sells prescription medicines and vaccines across internal medicine, oncology, immunology, rare disease and infectious disease, supported by global research, manufacturing and commercial operations. Biopharma is the sole reportable segment, and results depend on product approvals, payer access and replacing revenue as major medicines lose market exclusivity.
Discovers, develops, manufactures and sells prescription medicines and vaccines across internal medicine, oncology, vaccines, inflammation and immunology, rare disease and hospital care. Key franchises include the Eliquis anticoagulant, Prevnar pneumococcal vaccines, Vyndaqel cardiomyopathy treatments, Ibrance and Seagen-derived cancer medicines such as Padcev, plus Comirnaty and Paxlovid. Most revenue comes from the United States, with products sold across international markets.
Combines internal research with licensing, partnerships and acquisitions, then uses a global clinical, manufacturing and commercial network to move therapies from trials into regulated markets. Biopharma is the sole reportable segment; Pfizer CentreOne also provides contract development, manufacturing and specialty active ingredients. Revenue depends on regulatory approvals, payer access, successful clinical programs and patent protection, while several established medicines face generic or biosimilar competition as exclusivity expires.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 10, 2026 | HSBC | Reiterate | Rating: —Target: $28 | Target: $30 |
| Aug 7, 2026 | Guggenheim | Reiterate | Rating: —Target: $35 | Target: $31 |
| Jul 6, 2026 | HSBC | Downgrade | Target: $29 | Target: $28 |
| Jun 10, 2026 | RBC Capital | Upgrade | ||
| May 27, 2026 | UBS | Target | Target: $25 | Target: $27 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 28, 2026Cash & short-term investments $11.70B · Total debt $63.19B · Total assets $201.13B · Shareholders' equity $85.19B
- Revenue
- $15.03B
- Operating income
- $4.71B
- Net income
- −$246.0M
HistoryDividendAnnual yield
| Institutions | 67.82% | 3.87B shares | |
|---|---|---|---|
| 2,952 holders · as of Jun 30, 2026 | |||
| Insiders | 0.02% | 1.41M shares | |
| 13 holders · as of Aug 28, 2026 | |||
| Other | 32.16% | 1.83B shares | |
| remainder | |||
5.70B company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 9.29% | 529.67M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.53% | 372.15M | as of Jun 30, 2026 |
State Street CorpInstitution | 5.39% | 307.09M | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 2.37% | 135.28M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 2.09% | 119.24M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 12, 2026 | Albert Bourla | director, officer: Chairman & CEO | +38,000 | $26.34 |
| Aug 5, 2026 | Jennifer B. Damico | officer: SVP & Controller | −3,278 | $25.40 |
| Aug 5, 2026 | Mortimer J. Buckley | director | +37,632 | $25.52 |
| Aug 5, 2026 | Ronald E. Blaylock | director | +39,231 | $25.46 |
| Jun 9, 2026 | Jennifer B. Damico | officer: SVP & Controller | −2,000 | $25.70 |
- Merck
Keytruda oncology giant competing in cancer immunotherapy and adult vaccines.
- Eli Lilly
Dominant GLP-1 obesity/diabetes leader; defines the market Pfizer's Metsera must enter.
- Novo Nordisk (ADR)
GLP-1 obesity pioneer; conducted a direct Metsera bidding war against Pfizer in 2025.
- AstraZeneca (ADR)
ADC market leader via Enhertu; oncology share overlaps Pfizer's Seagen portfolio.
- AbbVie
Head-to-head in CGRP migraine; three-drug franchise spans acute, episodic, chronic.
- Bristol-Myers Squibb
Eliquis commercial partner and oncology rival via Opdivo in immuno-oncology.
- GSK (ADR)
Vaccine competitor in RSV (Arexvy vs Abrysvo) and adult immunization broadly.
- Moderna
Sole direct mRNA COVID vaccine rival; Spikevax competes with Comirnaty.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Pfizer | $27.51 | −0.85% | $158.10B | 36.7 | 9.8 | 2.5 | +2.6% |
| Merck | $148.13 | −0.92% | $369.24B | 119.6 | 17.2 | 5.6 | +5.1% |
| Eli Lilly | $1,140.00 | −2.14% | $1.10T | 39.1 | 27.9 | 13.8 | +47.7% |
| Novo Nordisk (ADR) | $39.38 | −1.05% | $176.83B | 9.9 | 16.2 | 3.5 | +1.3% |
| AstraZeneca (ADR) | $166.92 | −0.70% | $260.70B | 25.2 | 15.7 | 4.2 | +6.4% |
| AbbVie | $262.45 | −0.77% | $467.37B | 74.5 | 17.3 | 7.3 | +10.2% |
| Bristol-Myers Squibb | $62.06 | −0.90% | $127.91B | 13.8 | 9.7 | 2.6 | +5.7% |
| GSK (ADR) | $50.29 | −1.55% | $102.34B | 16.1 | 9.2 | 2.3 | +5.3% |
| Moderna | $171.67 | −0.74% | $68.62B | — | — | 30.8 | +2.1% |
| Median | 25.2 | 16.2 | 4.9 | +5.5% |